MétaCan
Menu
Back to cohort

Effect of Calcium Channel Blockers on Lung Function in Placebo-treated Patients in Idiopathic Pulmonary Fibrosis Trials

2025· article· en· W4410268380 on OpenAlexaff
Rayid Abdulqawi, Ghada Algwaiz, Haifa Aldakhil, Edward Devol, Imran Satia, Fasihul Khan, M.R.J. Kolb, Zainab Al Duhailib

Bibliographic record

VenueAmerican Journal of Respiratory and Critical Care Medicine · 2025
Typearticle
Languageen
FieldMedicine
TopicRespiratory and Cough-Related Research
Canadian institutionsMcMaster University
Fundersnot available
KeywordsMedicinePlaceboCalcium channelIdiopathic pulmonary fibrosisPulmonary function testingLung functionLungPulmonary fibrosisInternal medicineClinical trialCardiologyCalciumPathology

Abstract

fetched live from OpenAlex

Abstract Rationale: Currently, only two approved medications have been demonstrated to slow the progression of idiopathic pulmonary fibrosis (IPF). There remains an unmet need for more effective IPF therapies. Several preclinical studies have suggested that calcium channel blockers (CCBs) have potential antifibrotic effects. This study aims to evaluate the effect of CCBs on IPF progression. Methods: A post-hoc pooled analysis of data from placebo-treated participants in five IPF randomized clinical trials (RCTs) (CAPACITY-004, CAPACITY-006, ASCEND, INPULSIS-1, and INPULSIS-2) was conducted. Raw data from the Vivli platform were used following approval from the trial sponsors for secondary data analysis. The primary outcome was the change in percent (%) predicted forced vital capacity (FVC) from baseline to one year in patients on CCB at baseline compared to those not on CCB. The change was assessed using a three-level multilevel mixed-effects model, which accounts for the hierarchical structure of the data, with repeated measures (level 1) nested within individuals (level 2) nested within trials (level 3). Covariates included time (days since baseline), baseline CCB, trial- and participant-level baseline % predicted FVC, hypertension, and interactions with time. The secondary outcomes included the change in % predicted hemoglobin-corrected DLCO (DLCOcHb) and one-year survival, which was analyzed via Kaplan-Meier curves. Results: Among the placebo-treated patients, 13.2% (134/1013) were taking CCBs at baseline. There was evidence of a significant interaction effect between CCB use and time (p=0.037), suggesting that CCBs may slightly worsen the % predicted FVC over time. Overall, the % predicted FVC declined in absolute units by an average 6.77% per year for those not on CCBs. For the CCB group, there was an estimated additional 1.74% (95% CI: 0.1% to 3.51%) steeper average yearly decline, independent of hypertension (Figure). There was no significant differential effect of CCB use on changes in % predicted DLCOcHb. Additionally, there was no significant difference in the Kaplan-Meier estimated one-year survival between the groups (log-rank p=0.17). Conclusion: Post-hoc analysis of five previously conducted RCTs involving IPF patients revealed that CCBs were associated with a slightly steeper yearly decline in lung function. These data question the clinical relevance of the preclinical models suggesting benefits of CCBs.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.024
metaresearch head score (Gemma)0.029
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.024
Threshold uncertainty score0.127

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0240.029
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.004
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0040.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.358
Teacher spread0.336 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAmerican Journal of Respiratory and Critical Care MedicineSame topicRespiratory and Cough-Related ResearchFrench-language works237,207